Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)
December 9, 2025
December 9, 2025
Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults
December 9, 2025
December 9, 2025
Videoconference and publication of half-year financial results, Tuesday, December 9, 2025
December 1, 2025
December 1, 2025
Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference
